<DOC>
	<DOCNO>NCT02556463</DOCNO>
	<brief_summary>To evaluate MEDI9197 administered intratumoral injection subject solid tumor CTCL , combination durvalumab palliative radiation subject solid tumor .</brief_summary>
	<brief_title>A Study MEDI9197 Subjects With Solid Tumors CTCL Combination With Durvalumab Palliative Radiation Subjects With Solid Tumors</brief_title>
	<detailed_description>This multicenter , unblinded study evaluate TLR 7/8 agonist MEDI9197 deliver IT injection subject solid tumor CTCL , combination durvalumab palliative radiation subject solid tumor . The study use 3 + 3 dose escalation design evaluate range dos .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female subject least 18 year time screen 2 . Adequate organ function within 14 day enrollment confirm laboratory result 3 . Off immunosuppressive medication include , limited , systemic corticosteroid dose exceed 10 mg/day prednisone equivalent Additional Inclusion Criteria Part 1 : 1 . Metastatic/locally advanced solid tumor malignancy progress , refractory , standard care therapy 2 . At least one lesion easily accessible injection Additional Inclusion Criteria Subjects Part 2 1 . Clinical diagnosis CTCL , include documentation skin biopsy histological finding consistent CTCL 2 . Stage IB IIA disease : T1 T2 ( patch plaque ) measurable lesion 3 . Previous treatment least one standard therapy use treat Stage IB IIA CTCL 4 . At least 2 lesion amenable response assessment Additional Inclusion Criteria Subjects Part 3A 3B 1 . Metastatic/locally advanced solid tumor malignancy progress , refractory , standard care therapy Any follow would exclude subject participation study : 1 . Subjects receive prior immunotherapy NOT permit enroll unless follow apply : 1 . Prior antiCTLA 4 inhibitor last dose administer least 100 day ago . Other prior immunotherapy , last dose administer least 28 day prior plan first dose MEDI9197 2 . Must experience toxicity lead permanent discontinuation prior immunotherapy 3 . All AEs receive prior immunotherapy must resolve ≤ Grade 1 baseline prior screen study . Must experience ≥ Grade 3 AE neurologic , pneumonitis ocular AE grade receive prior immunotherapy 4 . Must require use additional immunosuppression corticosteroid management AE , experience recurrence AE rechallenged , currently require maintenance dos &gt; 10 mg prednisone equivalent per day 2 . Pregnant lactate 3 . Active bacterial , fungal , viral infection 4 . Active autoimmune disease , chronic inflammatory condition , condition require concurrent use systemic immunosuppressant steroids 5 . Immunedeficiency state myelodysplastic disorder , marrow failure , human immunodeficiency virus ( HIV ) infection , history solid organ transplant bone marrow allograft , recent pregnancy 6 . Requires continuous anticoagulation antiplatelet therapy . 7 . History coagulopathy result uncontrolled bleeding . 8 . Rapidly progress disease 9 . Untreated uncontrolled central nervous system ( CNS ) involvement . 10 . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment 11 . Unresolved toxicity prior anticancer therapy , define resolve NCI CTCAE v4.03 Grade 0 1 , exception alopecia , vitiligo laboratory value list per inclusion criterion 12 . Chronic active hepatitis B C 13 . Known allergy sesame oil and/or nuts 14 . Cardiac exclusion : New York Heart Association Class 3 4 congestive heart failure , uncontrolled hypertension , unstable angina pectoris , clinical important cardiac arrhythmia , mean QTC interval correct heart rate &gt; 500ms 15 . Major surgery within 4 week prior study entry still recover prior surgery 16 . Receipt live , attenuated vaccine within 28 day prior study entry . 17 . Receipt systemic anticancer therapy mention within last 2 week 5 halflives 18 . Subjects CTCL , must prior therapy Imiquimod , total body electron beam radiation , investigational drug treatment within 8 week . They must prior therapy local radiation , UBV therapy , PUVA , topical chemotherapy , photopheresis , systemic retinoids , corticosteroid , immune response modifier , IFN inducer , chemotherapeutic agent biological agent topical treatment within 4 week . They must know history positive test infection HTLV1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI9197</keyword>
	<keyword>TLR 7/8 Agonist</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>MEDI4736</keyword>
</DOC>